Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis

Summary

Tick saliva is a rich source of molecules with antiinflammatory, antihemostatic and immunosupressive properties. In this paper, a novel tick salivary gland cDNA with sequence homology to tissue factor pathway inhibitor (TFPI) and coding for a protein called Penthalaris has been characterized from the Lyme disease vector, Ixodes scapularis. Penthalaris is structurally unique and distinct from TFPI or TFPI-like molecules described so far, including Ixolaris, NAPc2, TFPI-1 and TFPI-2. Penthalaris is a 308-amino-acid protein (35 kDa, pI 8.58) with 12 cysteine bridges and 5 tandem Kunitz domains. Recombinant Penthalaris was expressed in insect cells and shown to inhibit factor VIIa (FVIIa)/tissue factor(TF)-induced factor X (FX) activation with an IC50 of ∼ 100 pM. Penthalaris tightly binds both zymogen FX and enzyme FXa (exosite), but not FVIIa, as demonstrated by column gel-filtration chromatography. At high concentrations, Penthalaris attenuates FVIIa/TF-induced chromogenic substrate (S2288) hydrolysis and FIX activation. In the presence of DEGR-FX or DEGR-FXa, but not des-Gla-DEGR-FXa as scaffolds, tight and stoichiometric inhibition of FVIIa/TF was achieved. In addition, Penthalaris blocks cell surface-mediated FXa generation by monomer (de-encrypted), but not dimer (encrypted) TF in HL-60 cells. Penthalaris may act in concert with Ixolaris and other salivary anti-hemostatics in order to help ticks to successfully feed on blood. Penthalaris is a novel anticoagulant and a tool to study FVIIa/TF-initiated biologic processes.

Keywords

Tissue factor pathway inhibitor - Ixodes scapularis - tick saliva - anticoagulant - Kunitz

• References

• 1 Broze GJ. Jr Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
• 2 Jenny NS, Mann KG. Coagulation cascade: an overview. in Loscalzo J, Schafer AI. (eds.): Thrombosis and Hemorrhage. 2d ed.. Baltimore, MD: Williams and Wilkins, 1998, 3-27.;
• 3 Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002; 12: 149-54.
• 4 Broze GJ. Jr Tissue factor pathway inhibitor. in Loscalzo J, Schafer AI. (eds.): Thrombosis and Hemorrhage. 2d ed. Baltimore, MD: Williams and Wilkins; 1998: 77-104.
• 5 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
• 6 Esmon CT. Regulation of Blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
• 7 Olson ST, Bjork I, Bock SC. Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants. Trends Cardiovasc Med 2002; 12: 198-205.
• 8 Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
• 9 Griffin JH. Control of coagulation reactions. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U. (eds): Williams Hematology. 6th ed. New York, NY: McGraw-Hill Companies, Inc; 2001: 1435-49.
• 10 Broze GJ, Jr Warren LA, Novotny WF. et al. The lipoprotein-associated coagulation inhibitor that inhibits the FVII-tissue factor complex also inhibits FXa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
• 11 Wun T-C, Kretzmer KK, Girard TJ. et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
• 12 Pedersen AH, Nordfang O, Norris F. et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factorinitiated coagulation reactions. J Biol Chem 1990; 254: 16786-93.
• 13 Hamamoto T, Yamamoto M, Nordfang O. et al. Inhibitory properties of full-length and truncated recombinant tisuue factor pathway inhibitor (TFPI). J Biol Chem 1993; 268: 8704-10.
• 14 Rapaport SI. Inhibition of FVIIa/tissue factor-induced blood coagulation: with particular emphasis upon a FXa-dependent inhibitory mechanism. Blood 1989; 73: 359-65.
• 15 Huang Z-F, Wun T-C, Broze Jr GJ. Kinetics of FXa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-5.
• 16 Rao LVM, Ruf W. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor-VIIa with Xa-tissue factor pathway inhibitor. Biochemistry 1995; 34: 10867-71.
• 17 Girard TJ, Warren LA, Novotny WF. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
• 18 Broze GJ, Jr Girard TH, Novotony WF. Regulation of coagulation by multivalent Kunitz-type inhibitor. Biochemistry 1995; 29: 7539-46.
• 19 Ruf W, Dickinson CD. Allosteric regulation of the cofactor dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 1988; 08: 350-6.
• 20 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating soluble, thrombogenic protein. Nat Med 2003; 09: 458-62.
• 21 Drake TA, Morrisey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134: 1087-97.
• 22 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-9.
• 23 Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-6.
• 24 Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 08: 385-90.
• 25 Camera M, Giesen PL, Fallon J. Cooperation between VEGF and TNF-α is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 531-7.
• 26 Giesen PLA, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-84.
• 27 Ribeiro JM, Francischetti IM. Role of arthropod saliva in blood feeding: sialome and post-sialome perspectives. Ann Rev Entomol 2003; 48: 73-88.
• 28 Sonenshine DE. Pheromones and other semiochemicals of the acari. Annu Rev Entomol 1985; 30: 1-28.
• 29 Francischetti IMB, Valenzuela JG, Andersen JF. et al. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002; 99: 3602-12.
• 30 Narasimhan S, Koski RA, Beaulieu B. et al. A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol Biol 2002; 11: 641-50.
• 31 Valenzuela JG, Charlab R, Mather TN. et al. Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J Biol Chem 2000; 275: 8717-23.
• 32 Ribeiro JMC, Makoul GT, Robinson DR. Ixodes dammini: evidence for salivary prostacyclin secretion. J Parasitol 1988; 74: 1068-9.
• 33 Mans BJ, Louw AI, Neitz AW. Savignygrin, a platelet aggregation inhibitor from the soft tick Ornithodoros savignyi, presents the RGD integrin recognition motif on the Kunitz-BPTI fold. J Biol Chem 2002; 277: 21371-8.
• 34 Ribeiro JMC, Weis JJ, Telford III SR. Saliva of the tick Ixodes dammini inhibits neutrophil function. Exp Parasitol 1990; 70: 382-8.
• 35 Francischetti IMB, Mather TN, Ribeiro JMC. Cloning of a salivary gland metalloprotease and characterization of gelatinase and fibrin- (ogen)lytic activities in the saliva of the Lyme disease tick vector Ixodes scapularis. Biochem Biophys Res Commun 2003; 305: 869-75.
• 36 Tatchell RJ. A modified method for obtaining tick oral secretion. J Parasitol 1967; 53: 1106-7.
• 37 Francischetti IMB, Valenzuela JG, Pham VM. et al. Toward a catalog for the transcripts and proteins (sialome) from the salivary gland of the malaria vector Anopheles gambiae. J Exp Biol 2002; 205: 2429-51.
• 38 Valenzuela JG, Francischetti IMB, Pham VM. et al. Exploring the sialome of the tick Ixodes scapularis. J Exp Biol 2002; 205: 2843-64.
• 39 Altschul SF, Madden TL, Schaffer AA. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 1997; 25: 3389-402.
• 40 Nielsen H, Engelbrecht J, Brunak S. et al. A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997; 10: 1-6.
• 41 Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22: 4673-80.
• 42 Page RDM. TREEVIEW: An application to display phylogenetic trees on personal computers. Computer Appl Biosci 1996; 12: 357-8.
• 43 Han X, Girard TJ, Baum P. et al. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999; 19: 2563-7.
• 44 Francischetti IMB, Andersen JF, Ribeiro JMC. Anophelin: kinetics and mechanism of thrombin inhibition. Biochemistry 1999; 38: 16678-85.
• 45 Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979; 63: 437-67.
• 46 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human FVIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1991; 29: 9418-25.
• 47 Bergun PW, Cruikshank A, Maki SL. et al. Role of zymogen and activated FX as scaffolds for the inhibition of the blood coagulation FVIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 2001; 276: 10063-71.
• 48 Baugh RJ, Dickinson CD, Ruf W. et al. Exosite interactions determine the affinity of FX for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-33.
• 49 Bode W, Huber R. Proteinase-protein inhibitor interaction. Biomed Biochim Acta 1991; 50: 437-46.
• 50 Huber R, Kukla D, Bode W. et al. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol 1974; 89: 73-101.
• 51 Laskowski Jr M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626.
• 52 Wesselschmidt R, Likert K, Huang Z. et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 04: 661-9.
• 53 Wesselschmidt R, Likert K, Girard T. et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of FXa. Blood 1992; 79: 2004-10.
• 54 Warshawasky I, Bu G, Mast A. et al. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1173-81.
• 55 Hembrough TA, Ruiz JF, Papathanassiu AE. et al. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001; 276: 12241-8.
• 56 Demchenko AP. Recognition between flexible protein molecules: induced and assisted folding. J Mol Recognit 2001; 14: 42-61.
• 57 Anderson PJ, Nesset A, Dharmawardana KR. et al. Characterization of proexosite I on prothrombin. J Biol Chem 2000; 275: 16428-34.
• 58 Rezaie AR. Identification of basic residues in the heparin-binding exosite of FXa critical for heparin and factor Va binding. J Biol Chem 2000; 275: 3320-7.
• 59 Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
• 60 Kossiakoff AA, Hynes T, de Vos A. Molecular recognition in biological systems: from activation to inhibition. Biochem Soc Trans 1993; 21: 614-8.
• 61 Roberts BL, Markland W, Ley AC. et al. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 1992; 89: 2429-33.
• 62 Waxman L, Smith DE, Arcuri KE. et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
• 63 Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-6.
• 64 van de Locht A, Stubbs MT, Bode W. et al. The ornithodorin-thrombin crystal structure, a key to the TAP enigma?. EMBO J 1996; 15: 6011-7.
• 65 Wei A, Alexander RS, Duke J. et al. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J Mol Biol 1998; 283: 147-54.
• 66 Dunwiddie CT, Waxman L, Vlasuk GP. et al. Purification and characterization of inhibitors of blood coagulation factor Xa from hematophagous organisms. Methods Enzymol 1993; 223: 291-312.
• 67 Mao SS, Huang J, Welebob C. et al. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa. Biochemistry 1995; 34: 5098-103.
• 68 Aitken A. Analysis of cysteine residues and disulfide bonds. Methods Mol Biol 1994; 32: 351-430.
• 69 Lindhout T, Fransen J, Willems G. Kinetics of the inhibition of tissue factor-FVIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-5.
• 70 Esnouf MP, Williams WJ. The isolation and purification of a bovine-plasma protein which is substrate for the coagulation fraction of Russell’s viper venom. Biochem J 1962; 84: 62-71.
• 71 Jackson CM, Hanahan DJ. Studies on bovine factor X. II. Observations on some alterations in zone electrophoresis and chromatographic behavior occurring during purification. Biochemistry 1968; 07: 4506-17.
• 72 Kirchhofer D, Lipari MT, Moran P. et al. The tissue factor region that interacts with substrates FIX and FX. Biochemistry 2000; 03: 7380-7.
• 73 Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease FVIIa. Proc Natl Acad Sci USA 1996; 93: 14379-84.
• 74 Roy S, Paborsky LR, Vehar GA. Self-association of tissue factor as revealed by chemical crosslinking. J Biol Chem 1991; 266: 4665-8.
• 75 Broze Jr GJ. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35.
• 76 Le DT, Rapaport SI, Rao LVM. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267: 15447-54.
• 77 Riewald M, Ruf W. Mechanism coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2003; 98: 7742-7.
• 78 Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-60.
• 79 Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107S.